# US 2016/0250285 A1 · Neuroprotective peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250285 A1
- Document ID: US20160250285A1
- Status: Published application
- Kind: A1
- Application number: 14/392,392
- Filed: 2014-10-30
- Published: 2016-09-01
- Earliest claimed: 2013-10-30
- Assignees: The University of Western Australia
- Applicants: University of Western Australia
- Inventors: Bruno Meloni
- Web page: https://patentgrep.com/patent/US20160250285A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/001: {by chemical synthesis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/02: for peripheral neuropathies
- A61P 25/16: Anti-Parkinson drugs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to the use of an isolated peptide of 10 to 32 amino acid residues in length for the treatment of neural injury, wherein the isolated peptide comprises at least 10 to 22 arginine residues. The peptide may be a poly-arg sequence or an arginine-rich peptide.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

An isolated peptide for the treatment or prevention of neural injury, said isolated peptide comprising 10 to 32 amino acid residues in length, wherein the isolated peptide includes at least 10 to 22 arginine residues.

### Claim 32 (depends on 31)

The peptide as claimed in claim 31, wherein the isolated peptide has an arginine content of at least 30%.

### Claim 33 (depends on 32)

The peptide as claimed in claim 32, wherein the isolated peptide has an arginine residue content of at least 90%.

### Claim 34 (depends on 31)

The peptide as claimed in claim 31, wherein the isolated peptide is a poly-arginine peptide comprising 10 to 18 arginine residues.

### Claim 35 (depends on 31)

The peptide as claimed in claim 31, wherein the isolated peptide comprises any one or more of the peptides selected from the group consisting of SEQ. ID. NOS. 7, 8, 9, 10, 11, 12, 13, 16, 22, 30, 31, 32, 33, 34, 35, 36, 37, and functional fragments and analogues thereof having neuroprotective activity.

### Claim 36 (depends on 31)

The peptide as claimed in claim 31, wherein the isolated peptide includes at least one poly-arginine segment comprising at least 4 contiguous arginine residues.

### Claim 37 (depends on 31)

The peptide as claimed in claim 31, wherein the isolated peptide comprises a mix of protamine derivatives.

### Claim 38 (depends on 37)

The peptide as claimed in claim 37, wherein the mix of protamine derivatives comprises protamine sulphate.

### Claim 39 (depends on 31)

The peptide as claimed in claim 31, wherein the isolated peptide treats or prevents neural injury by one or more mechanisms selected from the group consisting of promoting the survival of neurons, inhibiting neuronal cell death, affecting the endocytic processes of the cell; affecting the function of cell surface receptors to result in reduced cellular calcium influx; interacting with and/or stabilises the outer mitochondrial membrane to preserve mitochondrial function; and inhibiting, downregulating, or affecting the calcium-dependent pro-protein convertase enzyme furin.

### Claim 40 (depends on 32)

The peptide of claim 32, wherein the isolated peptide is included within, or fused to, one or more polypeptides.

### Claim 41 (depends on 40)

The peptide of claim 40, wherein the isolated peptide is fused to a second peptide with at least one linker sequence.

### Claim 42 (depends on 32)

The peptide of claim 32, wherein the isolated peptide exhibits neuroprotective activity at IC50 levels of less than 10 μM.

### Claim 43

An isolated polynucleotide sequence encoding a peptide for the treatment or prevention of neural injury, said polynucleotide sequence comprising:
a codon sequence coding for a 10 to 32 amino acid peptide having at least 10 to 22 arginine residues,
a complementary sequence that is complementary to the codon sequence,
a hybridization sequence that hybridizes under stringent conditions with the codon sequence, and
a homology sequence having at least 60% homology with the codon sequence,
wherein the isolated polynucleotide sequence is a non-naturally occurring polynucleotide, a man-made artificial construct, cDNA, or a vector including the isolated nucleic acids.

### Claim 44 (depends on 43)

The isolated polynucleotide sequence as claimed in claim 43, wherein the isolated polynucleotide sequence is incorporated into a pharmaceutical composition for the treatment or prevention of neural injury.

### Claim 45 (depends on 44)

The isolated polynucleotide sequence as claimed in claim 44, wherein the pharmaceutical composition is selected from the group consisting of ion exchangers, alumina, aluminium stearate, lecithin, serum proteins, buffers, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

### Claim 46

A pharmaceutical composition for the treatment or prevention of a neural injury, for promoting survival of neurons and/or for inhibiting cell death, the pharmaceutical composition or medicament including a peptide of 10 to 32 amino acid residues, wherein the peptide comprises at least 10 to 22 arginine residues.

### Claim 47 (depends on 45)

The pharmaceutical composition of claim 45, for use in the treatment or prevention of ischemia, perinatal hypoxia-ischemia, Alzheimer's disease, Huntington's Disease, Multiple Sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, stroke, peripheral neuropathy, spinal cord injury, pain or epilepsy.

### Claim 48 (depends on 45)

The pharmaceutical composition of claim 45, wherein a dosage for administration is from 0.001 mg/kg to 50 mg/kg.

### Claim 49 (depends on 48)

The pharmaceutical composition of claim 48, wherein the dosage is administered orally.

### Claim 50 (depends on 46)

The pharmaceutical composition of claim 46, wherein the pharmaceutical composition further includes carriers selected from the group consisting of ion exchangers, alumina, aluminium stearate, lecithin, serum proteins, buffers, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
